Literature DB >> 18795704

Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma.

Chien-Hua Chen1, Shang-Tao Lin, Chien-Long Kuo, Chiu-Kue Nien.   

Abstract

BACKGROUND/AIMS: Alpha-fetoprotein is often measured in subjects with chronic hepatitis C for diagnosing hepatocellular carcinoma. However, its prevalence and clinical significance remain inconclusive in subjects without hepatocellular carcinoma. The study was to assess the clinical, virologic, and histopathological significance of elevated AFP in chronic hepatitis C without the presence of hepatocellular carcinoma.
METHODOLOGY: The retrospective study enrolled 102 consecutive subjects with a histological diagnosis of chronic hepatitis C. None had evidence of hepatocellular carcinoma by image study at enrollment and for at least 6 months' follow-up. The correlation between serum alpha-fetoprotein level and clinical, virologic, or histopathological records was reviewed.
RESULTS: The prevalence of elevated serum alpha-fetoprotein (> or = 13.6 ug/L) was 28.4% (29/102) in this study. Hepatic steatosis (> or = 5% hepatocytes), hepatic fibrosis (> or = stage II), uric acid > or = 6.3 mg/dL, asparate aminotransferase > or = 40 IU/L, albumin < 3.5 g/dL, and fasting plasma glucose < 126 mg/dL were significantly associated with elevated AFP in multivariate analysis. However, neither hepatitis C virus genotype Ib infection nor viral load > or = 1x10(6) copies/ml was related to elevated AFP. A serum alpha-fetoprotein level of 15.6 ug/L was 34.3% sensitive and 83.6% specific for hepatic steatosis, was 28.2% sensitive and 95.8% specific for > or = stage II hepatic fibrosis in Chronic hepatitis C.
CONCLUSIONS: Elevated alpha-fetoprotein is independently associated with hepatic steatosis (> or = 5% hepatocytes), > or = stage II hepatic fibrosis, increased level of uric acid (> or = 6.3 mg/dL) or asparate aminotransferase (> or = 40 IU/L), and decreased level of albumin (< 3.5 g/dL) or fasting plasma glucose (< 126 mg/ dL). Viral factors, including hepatitis C virus genotype 1b infection and viral load, are not related to elevated alpha-fetoprotein in hepatitis C virus-infected subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795704

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Serum α-fetoprotein levels in liver steatosis.

Authors:  Ayşegül Babalı; Erman Cakal; Tuğrul Purnak; Ibrahim Bıyıkoğlu; Başak Cakal; Osman Yüksel; Seyfettin Köklü
Journal:  Hepatol Int       Date:  2009-11-05       Impact factor: 6.047

2.  Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection.

Authors:  Samer S El-Kamary; Mona M Mohamed; Maissa El-Raziky; Michelle D Shardell; Olfat G Shaker; Wafaa A ElAkel; Gamal Esmat
Journal:  Liver Int       Date:  2013-03-20       Impact factor: 5.828

3.  Dynamics of serum α-fetoprotein in viral hepatitis C without hepatocellular carcinoma.

Authors:  Teodora Isac; Sebastian Isac; Simona Ioanitescu; Enyedi Mihaly; Maria-Daniela Tanasescu; Daniela Gabriela Balan; Adrian Tulin; Laura Iliescu
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

4.  Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4.

Authors:  Nasser Mousa; Yahia Gad; Azza Abdel-Aziz; Ibrahem Abd-Elaal
Journal:  Int J Hepatol       Date:  2012-05-14

5.  Glypican 3 as a Serum Marker for Hepatoblastoma.

Authors:  Shengmei Zhou; Maurice R G O'Gorman; Fusheng Yang; Kevin Andresen; Larry Wang
Journal:  Sci Rep       Date:  2017-04-05       Impact factor: 4.379

Review 6.  Disease monitoring of hepatocellular carcinoma through metabolomics.

Authors:  Asem I Fitian; Roniel Cabrera
Journal:  World J Hepatol       Date:  2017-01-08

7.  The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.

Authors:  Xiangjun Qian; Yanna Liu; Fengping Wu; Siyu Zhang; Jiao Gong; Yuemin Nan; Bo Hu; Junhui Chen; Jingmin Zhao; Xiangmei Chen; Weidong Pan; Shuangsuo Dang; Fengmin Lu
Journal:  Viruses       Date:  2022-07-29       Impact factor: 5.818

8.  The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals.

Authors:  Hanan Mahmoud Fayed; Hasan Sedeek Mahmoud; Abdallah Elaiw Mohamed Ali
Journal:  Clin Exp Gastroenterol       Date:  2020-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.